BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...

Geron Corporation’s GERN share price has surged by 10.63%, which has investors questioning if this is right time to sell.

Black women with chronic myeloid leukemia face unique challenges when it comes to diagnosis, treatment, and overall disease ...

ALX Oncology Holdings Inc.’s ALXO share price has dipped by 19.08%, which has investors questioning if this is right time to ...

By Daniella Parra Ascentage Pharma (NASDAQ: AAPG; HKEX) said that its drug Olverembatinib is the first China-approved ...

Ascentage Pharma (AAPG) announced that its drug, olverembatinib, has been granted a Breakthrough Therapy Designation by the Center for Drug ...

Myeloid cells constitute essential components within the immunosuppressive microenvironment of various tumors, significantly influencing cancer progression ...

In The Lancet Hematology, Jorge E Cortes and colleagues1 report a phase 1/2 study on vodobatinib in patients with resistance or intolerance mainly to third-line or later lines of therapy. Vodabatinib ...

The first line of innate immunological defense against particles are myeloid-lineage phagocytes, namely macrophages and neutrophils, which recognize/internalize the particles, release inflammatory ...

Acute myeloid leukemia (AML) is a cancer of immature blood cells. When the early myeloid cell matures normally, it will become either a mature white blood cell, red blood cell, or platelet.

That's the bottom line." More information: Xiaoyan Hu et al, Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia, Signal Transduction and Targeted Therapy (2025). DOI: ...

Scientists have identified an innovative combination of treatment strategies that work collaboratively to effectively kill acute myeloid leukemia (AML) cells, a frequently incurable form of cancer.